# Edinburgh Cancer Research

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/edinburgh-cancer-research/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 87.3 |
| Citations | 695,904 |
| City | Edinburgh |
| Country | GB |
| Description | Edinburgh Cancer Research is a research organisation in Edinburgh, GB. OpenAlex records 6,063 works and 695,904 citations for it. 1,270 researchers list it as their most recent affiliation. |
| Homepage | https://www.ed.ac.uk/cancer-centre |
| OpenAlex ID | https://openalex.org/I2802581871 |
| Researchers | 1,270 |
| ROR ID | https://ror.org/05a7t9b67 |
| Type | facility |
| Wikidata ID | https://www.wikidata.org/wiki/Q16974412 |
| Works | 6,063 |

## University papers

Showing 12 of 103.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis](https://scholariq.org/papers/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer/)
- [Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial](https://scholariq.org/papers/primary-prevention-of-cardiovascular-disease-with-atorvastatin-in-type-2/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-obesity-without-diabetes/)
- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Epithelial ovarian cancer](https://scholariq.org/papers/epithelial-ovarian-cancer/)
- [Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer](https://scholariq.org/papers/olaparib-maintenance-therapy-in-platinum-sensitive-relapsed-ovarian-cancer/)
- [Resolving the fibrotic niche of human liver cirrhosis at single-cell level](https://scholariq.org/papers/resolving-the-fibrotic-niche-of-human-liver-cirrhosis-at-single-cell-level/)

## University researchers

- [Helen M. Colhoun](https://scholariq.org/researchers/helen-m-colhoun/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Epigenetics and DNA Methylation](https://scholariq.org/topics/epigenetics-and-dna-methylation/)
- [Genetic Associations and Epidemiology](https://scholariq.org/topics/genetic-associations-and-epidemiology/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.